Design and applications of bispecific heterodimers: Molecular imaging and beyond

Molecular Pharmaceutics

Volumn 11, Issue 6, 2014, Pages 1750-1761

  Luo, Haiming ^a   Hong, Hao ^a   Yang, Sarah P ^b   Cai, Weibo ^a,b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

bispecific antibodies; cancer; dual targeting; heterobivalent ligands; molecular imaging; positron emission tomography (PET)

Indexed keywords

1,4,7 TRIAZACYCLONONANE TRIACETIC ACID ARGINYLGLYCYLASPARTIC ACID BOMBESIN GA 68; 1,4,7 TRIAZACYCLONONANE TRIACETIC ACID ARGINYLGLYCYLASPARTIC ACID GA 68; 1,4,7 TRIAZACYCLONONANE TRIACETIC ACID BOMBESIN GA 68; BISPECIFIC ANTIBODY; BOMBESIN DERIVATIVE; CD20 ANTIBODY; DIPHTHERIA TOXIN; FLUOROBENZYLARGINYLGLYCYLASPARTIC ACID BOMBESIN F 18; FLUOROBENZYLARGINYLGLYCYLASPARTIC ACID F 18; FLUOROBENZYLBOMBESIN F 18; GEMTUZUMAB; GOLD NANOPARTICLE; HETERODIMER; IMMUNOTOXIN; ISOTHIOCYANATOBENZYL 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID I 125; MONOCLONAL ANTIBODY; NANOMATERIAL; PEPTIDE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT DNA; TRASTUZUMAB; UNCLASSIFIED DRUG; LIGAND; MOLECULAR PROBE;

ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; CROSS LINKING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR BIOLOGY; MOLECULAR IMAGING; NONHUMAN; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DIMERIZATION; MOLECULAR PROBE; PROCEDURES;

ANIMALS; ANTIBODIES, BISPECIFIC; DIMERIZATION; HUMANS; LIGANDS; MOLECULAR IMAGING; MOLECULAR PROBES; NANOSTRUCTURES; PEPTIDES;

EID: 84901807644     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500115x     Document Type: Article

References (118)

1. Schottelius, M.; Wester, H. J. Molecular imaging targeting peptide receptors Methods 2009, 48, 161-77
2. James, M. L.; Gambhir, S. S. A molecular imaging primer: modalities, imaging agents, and applications Physiol. Rev. 2012, 92, 897-965
3. Mankoff, D. A. A definition of molecular imaging J. Nucl. Med. 2007, 48, 18N-21N
4. Pysz, M. A.; Gambhir, S. S.; Willmann, J. K. Molecular imaging: current status and emerging strategies Clin. Radiol. 2010, 65, 500-16
5. 68Ga-DOTATATE in patients with neuroendocrine tumors J. Nucl. Med. 2013, 54, 1755-9
6. Pepe, G.; Moncayo, R.; Bombardieri, E.; Chiti, A. Somatostatin receptor SPECT Eur. J. Nucl. Med. Mol. Imaging 2012, 39, S41-51
7. Capala, J.; Bouchelouche, K. Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy Curr. Opin. Oncol. 2010, 22, 559-66
8. 89Zr-bevacizumab PET imaging in primary breast cancer J. Nucl. Med. 2013, 54, 1014-8
9. Noguera, E. C.; Palazzo, E.; Mayoraz, M. F.; Diller, A.; Burgesser, M. V.; Jaime, A.; Borello, A.; Avila, R.; Mondina, J. C. Technetium-bevacizumab in a patient with bone and lung metastatic colon adenocarcinoma J. Clin. Oncol. 2013, 31, e170-2
10. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation Cell 2011, 144, 646-74
11. Baeriswyl, V.; Christofori, G. The angiogenic switch in carcinogenesis Semin. Cancer Biol. 2009, 19, 329-37
12. Gerlinger, M.; Rowan, A. J.; Horswell, S.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; Tarpey, P.; Varela, I.; Phillimore, B.; Begum, S.; McDonald, N. Q.; Butler, A.; Jones, D.; Raine, K.; Latimer, C.; Santos, C. R.; Nohadani, M.; Eklund, A. C.; Spencer-Dene, B.; Clark, G.; Pickering, L.; Stamp, G.; Gore, M.; Szallasi, Z.; Downward, J.; Futreal, P. A.; Swanton, C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N. Engl. J. Med. 2012, 366, 883-92
13. Fisher, R.; Pusztai, L.; Swanton, C. Cancer heterogeneity: implications for targeted therapeutics Br. J. Cancer 2013, 108, 479-85
14. Saga, T.; Neumann, R. D.; Heya, T.; Sato, J.; Kinuya, S.; Le, N.; Paik, C. H.; Weinstein, J. N. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8999-9003
15. Mohd Sharial, M. S.; Crown, J.; Hennessy, B. T. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer Ann. Oncol. 2012, 23, 3007-16
16. Rosenzweig, S. A. Acquired resistance to drugs targeting receptor tyrosine kinases Biochem. Pharmacol. 2012, 83, 1041-8
17. Cochran, J. R. Engineered proteins pull double duty Sci. Transl. Med. 2010, 2, 17ps5
18. Banta, S.; Dooley, K.; Shur, O. Replacing antibodies: engineering new binding proteins Annu. Rev. Biomed. Eng. 2013, 15, 93-113
19. 99mTc-labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma Mol. Pharm. 2012, 9, 1409-17
20. 64Cu-labeled RGD-bombesin heterodimer J. Nucl. Med. 2009, 50, 1168-77
21. Kellner, C.; Bruenke, J.; Stieglmaier, J.; Schwemmlein, M.; Schwenkert, M.; Singer, H.; Mentz, K.; Peipp, M.; Lang, P.; Oduncu, F.; Stockmeyer, B.; Fey, G. H. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells J. Immunother. 2008, 31, 871-84
22. Muller, D.; Kontermann, R. E. Bispecific antibodies for cancer immunotherapy: current perspectives BioDrugs 2010, 24, 89-98
23. Papo, N.; Silverman, A. P.; Lahti, J. L.; Cochran, J. R. Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 14067-72
24. 18F-FB- PEG3-Glu-RGD-BBN J. Med. Chem. 2009, 52, 425-32
25. Josan, J. S.; Handl, H. L.; Sankaranarayanan, R.; Xu, L.; Lynch, R. M.; Vagner, J.; Mash, E. A.; Hruby, V. J.; Gillies, R. J. Cell-specific targeting by heterobivalent ligands Bioconjugate Chem. 2011, 22, 1270-8
26. Xu, L.; Josan, J. S.; Vagner, J.; Caplan, M. R.; Hruby, V. J.; Mash, E. A.; Lynch, R. M.; Morse, D. L.; Gillies, R. J. Heterobivalent ligands target cell-surface receptor combinations in vivo Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 21295-300
27. Vauquelin, G.; Charlton, S. J. Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands Br. J. Pharmacol. 2013, 168, 1771-85
28. Kim, E. M.; Jeong, M. H.; Kim, D. W.; Jeong, H. J.; Lim, S. T.; Sohn, M. H. Iodine 125-labeled mesenchymal-epithelial transition factor binding peptide-click-cRGDyk heterodimer for glioma imaging Cancer Sci. 2011, 102, 1516-21
29. Wu, A. M.; Olafsen, T. Antibodies for molecular imaging of cancer Cancer J. 2008, 14, 191-7
30. Byrne, H.; Conroy, P. J.; Whisstock, J. C.; O'Kennedy, R. J. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications Trends Biotechnol. 2013, 31, 621-32
31. Das, D.; Suresh, M. R. Producing bispecific and bifunctional antibodies Methods Mol. Med. 2005, 109, 329-46
32. Brennan, M.; Davison, P. F.; Paulus, H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments Science 1985, 229, 81-3
33. 2 formation in Escherichia coli and for improved in vivo stability J. Immunol. 1993, 151, 6954-61
34. Vuillez, J. P.; Moro, D.; Brichon, P. Y.; Rouvier, E.; Brambilla, E.; Barbet, J.; Peltier, P.; Meyer, P.; Sarrazin, R.; Brambilla, C. Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer J. Nucl. Med. 1997, 38, 507-11
35. 2 antibody containing thioether-linked Fab′ gamma fragments J. Immunol. 1987, 139, 2367-75
36. Hosono, M.; Hosono, M. N.; Kraeber-Bodere, F.; Devys, A.; Thedrez, P.; Fiche, M.; Gautherot, E.; Barbet, J.; Chatal, J. F. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten J. Nucl. Med. 1998, 39, 1608-13
37. Gundlach, C. W.; Caivano, A.; Cabreira-Hansen Mda, G.; Gahremanpour, A.; Brown, W. S.; Zheng, Y.; McIntyre, B. W.; Willerson, J. T.; Dixon, R. A.; Perin, E. C.; Woodside, D. G. Synthesis and evaluation of an anti-MLC1 × anti-CD90 bispecific antibody for targeting and retaining bone-marrow-derived multipotent stromal cells in infarcted myocardium Bioconjugate Chem. 2011, 22, 1706-14
38. Thakur, A.; Lum, L. G. Cancer therapy with bispecific antibodies: clinical experience Curr. Opin. Mol. Ther. 2010, 12, 340-9
39. Milstein, C.; Cuello, A. C. Hybrid hybridomas and their use in immunohistochemistry Nature 1983, 305, 537-40
40. Kriangkum, J.; Xu, B.; Nagata, L. P.; Fulton, R. E.; Suresh, M. R. Bispecific and bifunctional single chain recombinant antibodies Biomol. Eng. 2001, 18, 31-40
41. Zapata, G.; Ridgway, J. B. B.; Mordenti, J.; Osaka, G.; Wong, W. L. T.; Bennett, G. L.; Carter, P. Engineering linear F(ab′)2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity Protein Eng. 1995, 8, 1057-62
42. Kroesen, B. J.; Nieken, J.; Sleijfer, D. T.; Molema, G.; de Vries, E. G.; Groen, H. J.; Helfrich, W.; The, T. H.; Mulder, N. H.; de Leij, L. Approaches to lung cancer treatment using the CD3 × EGP-2-directed bispecific monoclonal antibody BIS-1 Cancer Immunol. Immunther. 1997, 45, 203-6
43. deKruif, J.; Logtenberg, T. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library J. Biol. Chem. 1996, 271, 7630-34
44. Kostelny, S. A.; Cole, M. S.; Tso, J. Y. Formation of a bispecific antibody by the use of leucine zippers J. Immunol. 1992, 148, 1547-53
45. Mack, M.; Riethmuller, G.; Kufer, P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor-cell cytotoxicity Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7021-25
46. Robinson, M. K.; Hodge, K. M.; Horak, E.; Sundberg, A. L.; Russeva, M.; Shaller, C. C.; von Mehren, M.; Shchaveleva, I.; Simmons, H. H.; Marks, J. D.; Adams, G. P. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro Br. J. Cancer 2008, 99, 1415-25
47. Pack, P.; Pluckthun, A. Miniantibodies-use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli Biochemistry 1992, 31, 1579-84
48. Luo, D.; Geng, M.; Noujaim, A. A.; Madiyalakan, R. An engineered bivalent single-chain antibody fragment that increases antigen binding activity J. Biochem.-Tokyo 1997, 121, 831-34
49. Muller, K. M.; Arndt, K. M.; Pluckthun, A. A dimeric bispecific miniantibody combines two specificities with avidity FEBS Lett. 1998, 432, 45-9
50. Deyev, S. M.; Waibel, R.; Lebedenko, E. N.; Schubiger, A. P.; Pluckthun, A. Design of multivalent complexes using the barnase-barstar module Nat. Biotechnol. 2003, 21, 1486-92
51. Spang, H. C.; Braathen, R.; Bogen, B. Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells PLoS One 2012, 7, e45393
52. Kontermann, R. Dual targeting strategies with bispecific antibodies MAbs 2012, 4, 182-97
53. Kufer, P.; Lutterbuse, R.; Baeuerle, P. A. A revival of bispecific antibodies Trends Biotechnol. 2004, 22, 238-44
54. Schoonjans, R.; Willems, A.; Schoonooghe, S.; Leoen, J.; Grooten, J.; Mertens, N. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain Biomol. Eng. 2001, 17, 193-202
55. Schoonjans, R.; Willems, A.; Schoonooghe, S.; Fiers, W.; Grooten, J.; Mertens, N. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives J. Immunol. 2000, 165, 7050-57
56. Lu, H.; Shi, M.; Wang, M.; Xie, Z.; Hu, M.; Yu, M.; Shen, B.; Ma, Y.; Guo, N. In vitro and in vivo antitumor effect of a trivalent bispecific antibody targeting ErbB2 and CD16 Cancer Biol. Ther. 2008, 7, 1744-50
57. Muller, K. M.; Arndt, K. M.; Strittmatter, W.; Pluckthun, A. The first constant domain (C(H)1 and C-L) of an antibody used as heterodimerization domain for bispecific miniantibodies FEBS Lett. 1998, 422, 259-64
58. Zhu, Z. P.; Presta, L. G.; Zapata, G.; Carter, P. Remodeling domain interfaces to enhance heterodimer formation Protein Sci. 1997, 6, 781-88
59. Gunasekaran, K.; Pentony, M.; Shen, M.; Garrett, L.; Forte, C.; Woodward, A.; Bin Ng, S.; Born, T.; Retter, M.; Manchulenko, K.; Sweet, H.; Foltz, I. N.; Wittekind, M.; Yan, W. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG J. Biol. Chem. 2010, 285, 19637-46
60. Presta, L. G. Molecular engineering and design of therapeutic antibodies Curr. Opin. Immunol. 2008, 20, 460-70
61. Carter, P. Bispecific human IgG by design J. Immunol. Methods 2001, 248, 7-15
62. Woods, R. J.; Xie, M. H.; Von Kreudenstein, T. S.; Ng, G. Y.; Dixit, S. B. LC-MS characterization and purity assessment of a prototype bispecific antibody MAbs 2013, 5, 711-22
63. Merchant, A. M.; Zhu, Z.; Yuan, J. Q.; Goddard, A.; Adams, C. W.; Presta, L. G.; Carter, P. An efficient route to human bispecific IgG Nat. Biotechnol. 1998, 16, 677-81
64. Klein, C.; Sustmann, C.; Thomas, M.; Stubenrauch, K.; Croasdale, R.; Schanzer, J.; Brinkmann, U.; Kettenberger, H.; Regula, J. T.; Schaefer, W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies MAbs 2012, 4, 653-63
65. Ridgway, J. B.; Presta, L. G.; Carter, P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization Protein Eng. 1996, 9, 617-21
66. Choi, H. J.; Kim, Y. J.; Lee, S.; Kim, Y. S. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity Mol. Cancer Ther. 2013, 12, 2748-59
67. Schaefer, W.; Regula, J. T.; Bahner, M.; Schanzer, J.; Croasdale, R.; Durr, H.; Gassner, C.; Georges, G.; Kettenberger, H.; Imhof-Jung, S.; Schwaiger, M.; Stubenrauch, K. G.; Sustmann, C.; Thomas, M.; Scheuer, W.; Klein, C. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 11187-92
68. Labrijn, A. F.; Buijsse, A. O.; van den Bremer, E. T. J.; Verwilligen, A. Y. W.; Bleeker, W. K.; Thorpe, S. J.; Killestein, J.; Polman, C. H.; Aalberse, R. C.; Schuurman, J.; van de Winkel, J. G. J.; Parren, P. W. H. I. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo Nat. Biotechnol. 2009, 27, 767-71
69. Strop, P.; Ho, W. H.; Boustany, L. M.; Abdiche, Y. N.; Lindquist, K. C.; Farias, S. E.; Rickert, M.; Appah, C. T.; Pascua, E.; Radcliffe, T.; Sutton, J.; Chaparro-Riggers, J.; Chen, W.; Casas, M. G.; Chin, S. M.; Wong, O. K.; Liu, S. H.; Vergara, G.; Shelton, D.; Rajpal, A.; Pons, J. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair J. Mol. Biol. 2012, 420, 204-19
70. Spiess, C.; Merchant, M.; Huang, A.; Zheng, Z.; Yang, N. Y.; Peng, J.; Ellerman, D.; Shatz, W.; Reilly, D.; Yansura, D. G.; Scheer, J. M. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies Nat. Biotechnol. 2013, 31, 753-8
71. Fani, M.; Maecke, H. R. Radiopharmaceutical development of radiolabelled peptides Eur. J. Nucl. Med. Mol. Imaging 2012, 39, S11-30
72. Li, Z. J.; Cho, C. H. Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery J. Transl. Med. 2012, 10, S1
73. Reubi, J. C.; Schar, J. C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J. S.; Macke, H. R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur. J. Nucl. Med. 2000, 27, 273-82
74. Susini, C.; Buscail, L. Rationale for the use of somatostatin analogs as antitumor agents Ann. Oncol. 2006, 17, 1733-42
75. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging J. Nucl. Med. 2008, 49, 453-61
76. 99mTc-NC100692 J. Nucl. Med. 2006, 47, 1434-9
77. Ruoslahti, E.; Pierschbacher, M. D. New perspectives in cell adhesion: RGD and integrins Science 1987, 238, 491-7
78. Cornelio, D. B.; Roesler, R.; Schwartsmann, G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy Ann. Oncol. 2007, 18, 1457-66
79. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 1483-94
80. Koopmans, K. P.; Glaudemans, A. W. Rationale for the use of radiolabelled peptides in diagnosis and therapy Eur. J. Nucl. Med. Mol. Imaging 2012, 39, S4-10
81. Roivainen, A.; Jalkanen, S.; Nanni, C. Gallium-labelled peptides for imaging of inflammation Eur. J. Nucl. Med. Mol. Imaging 2012, 39, S68-77
82. Kolaczkowska, E.; Kubes, P. Neutrophil recruitment and function in health and inflammation Nat. Rev. Immunol. 2013, 13, 159-75
83. Babich, J. W.; Tompkins, R. G.; Graham, W.; Barrow, S. A.; Fischman, A. J. Localization of radiolabeled chemotactic peptide at focal sites of Escherichia coli infection in rabbits: evidence for a receptor-specific mechanism J. Nucl. Med. 1997, 38, 1316-22
84. 64Cu J. Nucl. Med. 2009, 50, 790-7
85. 99mTc Bioconjugate Chem. 2010, 21, 1788-93
86. Pinkas-Kramarski, R.; Soussan, L.; Waterman, H.; Levkowitz, G.; Alroy, I.; Klapper, L.; Lavi, S.; Seger, R.; Ratzkin, B. J.; Sela, M.; Yarden, Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions EMBO J. 1996, 15, 2452-67
87. Hynes, N. E.; Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors Nat. Rev. Cancer 2005, 5, 341-54
88. Adams, G. P.; Tai, M. S.; McCartney, J. E.; Marks, J. D.; Stafford, W. F.; Houston, L. L.; Huston, J. S.; Weiner, L. M. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers Clin. Cancer Res. 2006, 12, 1599-1605
89. Razumienko, E. J.; Scollard, D. A.; Reilly, R. M. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates J. Nucl. Med. 2012, 53, 1943-50
90. Agus, D. B.; Akita, R. W.; Fox, W. D.; Lewis, G. D.; Higgins, B.; Pisacane, P. I.; Lofgren, J. A.; Tindell, C.; Evans, D. P.; Maiese, K.; Scher, H. I.; Sliwkowski, M. X. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Cancer Cell 2002, 2, 127-37
91. Razumienko, E.; Dryden, L.; Scollard, D.; Reilly, R. M. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using In-111-labeled bispecific radioimmunoconjugates Breast Cancer Res. Treat. 2013, 138, 709-18
92. Staerz, U. D.; Kanagawa, O.; Bevan, M. J. Hybrid antibodies can target sites for attack by T-cells Nature 1985, 314, 628-31
93. Wallace, P. K.; Romet-Lemonne, J. L.; Chokri, M.; Kasper, L. H.; Fanger, M. W.; Fadul, C. E. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to Fc gamma RI and the epidermal growth factor receptor Cancer Immunol. Immunther. 2000, 49, 493-503
94. Hombach, A.; Jung, W.; Pohl, C.; Renner, C.; Sahin, U.; Schmits, R.; Wolf, J.; Kapp, U.; Diehl, V.; Pfreundschuh, M. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo Int. J. Cancer 1993, 55, 830-6
95. Riethmuller, G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on Cancer Immun. 2012, 12, 12
96. De Jonge, J.; Heirman, C.; de Veerman, M.; Van Meirvenne, S.; Moser, M.; Leo, O.; Thielemans, K. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 × anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model J. Immunol. 1998, 161, 1454-61
97. Fleuren, G. J.; Gorter, A.; Kuppen, P. J.; Litvinov, S.; Warnaar, S. O. Tumor heterogeneity and immunotherapy of cancer Immunol. Rev. 1995, 145, 91-122
98. 2HER2× CD3 Cancer Res. 2002, 62, 5785-91
99. Maher, J. Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells Curr. Gene Ther. 2013, 14, 35-43
100. Cochlovius, B.; Kipriyanov, S. M.; Stassar, M. J.; Christ, O.; Schuhmacher, J.; Strauss, G.; Moldenhauer, G.; Little, M. Treatment of human B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells J. Immunol. 2000, 165, 888-95
101. Stone, M. J.; Sausville, E. A.; Fay, J. W.; Headlee, D.; Collins, R. H.; Figg, W. D.; Stetler-Stevenson, M.; Jain, V.; Jaffe, E. S.; Solomon, D.; Lush, R. M.; Senderowicz, A.; Ghetie, V.; Schindler, J.; Uhr, J. W.; Vitetta, E. S. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma Blood 1996, 88, 1188-97
102. Kreitman, R. J.; Wilson, W. H.; Bergeron, K.; Raggio, M.; Stetler-Stevenson, M.; FitzGerald, D. J.; Pastan, I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia N. Engl. J. Med. 2001, 345, 241-7
103. Vallera, D. A.; Todhunter, D. A.; Kuroki, D. W.; Shu, Y.; Sicheneder, A.; Chen, H. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma Clin. Cancer Res. 2005, 11, 3879-88
104. Gao, H.; Yang, Z.; Zhang, S.; Pang, Z.; Liu, Q.; Jiang, X. Study and evaluation of mechanisms of dual targeting drug delivery system with tumor microenvironment assays compared with normal assays Acta Biomater. 2014, 10, 858-67
105. Gao, H.; Yang, Z.; Cao, S.; Xiong, Y.; Zhang, S.; Pang, Z.; Jiang, X. Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment Biomaterials 2014, 35, 2374-82
106. Jing, F.; Li, D.; Xu, W.; Liu, Y.; Wang, K.; Sui, Z. Transferrin- and folate-modified, double-targeted nanocarriers for gene delivery Pharm. Biol. 2014, 52, 570-4
107. Mohamed, M. S.; Veeranarayanan, S.; Poulose, A. C.; Nagaoka, Y.; Minegishi, H.; Yoshida, Y.; Maekawa, T.; Kumar, D. S. Type 1 ribotoxin-curcin conjugated biogenic gold nanoparticles for a multimodal therapeutic approach towards brain cancer Biochim. Biophys. Acta 2013, 1840, 1657-69
108. Rangger, C.; Helbok, A.; Sosabowski, J.; Kremser, C.; Koehler, G.; Prassl, R.; Andreae, F.; Virgolini, I. J.; von Guggenberg, E.; Decristoforo, C. Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles Int. J. Nanomed. 2013, 8, 4659-71
109. Hattori, T.; Umetsu, M.; Nakanishi, T.; Sawai, S.; Kikuchi, S.; Asano, R.; Kumagai, I. A high-affinity gold-binding camel antibody: antibody engineering for one-pot functionalization of gold nanoparticles as biointerface molecules Bioconjugate Chem. 2012, 23, 1934-44
110. Watanabe, H.; Nakanishi, T.; Umetsu, M.; Kumagai, I. Human anti-gold antibodies: biofunctionalization of gold nanoparticles and surfaces with anti-gold antibodies J. Biol. Chem. 2008, 283, 36031-38
111. Yeheskely-Hayon, D.; Minai, L.; Golan, L.; Dann, E. J.; Yelin, D. Optically induced cell fusion using bispecific nanoparticles Small 2013, 9, 3771-7
112. Hudson, P. J.; Kortt, A. A. High avidity scFv multimers; diabodies and triabodies J. Immunol. Methods 1999, 231, 177-89
113. Atwell, J. L.; Breheney, K. A.; Lawrence, L. J.; McCoy, A. J.; Kortt, A. A.; Hudson, P. J. scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies Protein Eng. 1999, 12, 597-604
114. Le Gall, F.; Kipriyanov, S. M.; Moldenhauer, G.; Little, M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding FEBS Lett. 1999, 453, 164-8
115. Vallera, D. A.; Chen, H.; Sicheneder, A. R.; Panoskaltsis-Mortari, A.; Taras, E. P. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy Leuk. Res. 2009, 33, 1233-42
116. 68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer Bioconjugate Chem. 2009, 20, 1016-25
117. Shrivastava, A.; Wang, S. H.; Raju, N.; Gierach, I.; Ding, H.; Tweedle, M. F. Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells Bioorg. Med. Chem. Lett. 2013, 23, 687-92
118. Xu, L.; Vagner, J.; Josan, J.; Lynch, R. M.; Morse, D. L.; Baggett, B.; Han, H.; Mash, E. A.; Hruby, V. J.; Gillies, R. J. Enhanced targeting with heterobivalent ligands Mol. Cancer Ther. 2009, 8, 2356-65